New Report Analyses Therapeutic Proteins for Assisted Reproductive Technology

Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has added a new report providing an analysis in the development pipeline of novel recombinant...
By: Jonna Dagliden
 
Nov. 18, 2009 - PRLog -- Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has added a new report providing an analysis in the development pipeline of novel recombinant, transgenic and oral FSH, hCG and LH receptor agonists for treatment of infertility.

“FSH, hCG and LH - Therapeutic Proteins for Assisted Reproductive Technology (ART)
Competitor Analysis”, which is available from tinyurl.com/yd5xw9g reports that Follicle-stimulating hormone (FSH) now has become an established means of ovulation induction (OI) as part of assisted reproductive technology (ART).

The report shows that FSH is used to induce development of multiple follicles in ovulatory women and anovulatory infertile women. The major recombinant FSH products posted 2008 sales of $ 1.25 bln.

Authors of the report note that current recombinant (follitropin) as well as highly purified human urinary (urofollitropin) FSH preparations have replaced earlier products with painful IM administrations.

Current focus of new development lies on longer-acting and needle-free preparations. The most advanced projects are in registration or late clinical development. Other innovations in FSH research and development are modern production technologies in new expression systems such as plants or transgenic animals. The search for more effective FSH is ongoing and oral FSH receptor agonists have been identified.

The report describes the market size of major FSH products, provides information on the marketed FSH, hCG and LH preparations and includes a compilation of current active projects in research and development of novel FSH, LH and hCG receptor agonists. Competitor projects are listed in a tabular format providing information on:

*Drug Codes,
*Target / Mechanism of Action,
*Class of Compound,
*Company,
*Product Category,
*Indication,
*R&D Stage and
*additional comments with a hyperlink leading to the source of information.

“FSH, hCG and LH - Therapeutic Proteins for Assisted Reproductive Technology (ART)
Competitor Analysis” is available from Piribo. For more information go to: http://www.piribo.com/publications/diseases_conditions/fs...

Piribo product ID: LME00109

# # #

About Piribo.
Piribo (http://www.piribo.com/publications/diseases_conditions/in...) is a UK-based independent online store supplying business information on the pharmaceutical and biotechnology industries. The website now carries over 17,000 English language titles including, market reports, studies and books and is the UK’s largest online biopharma information store. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. The company was established in 2004.
End
Source:Jonna Dagliden
Email:***@piribo.com Email Verified
Zip:SE1 3LJ
Tags:Therapeutic, Proteins, Assisted Reproductive Technology
Industry:Medical
Location:London City - London, Greater - England
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Piribo News
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share